Abstract: Inavolisib (GDC-0077) is a highly selective, third-generation phosphoinositide 3-kinase alpha (PI3Kα) inhibitor and mutant p110α degrader that has recently emerged as a transformative targeted therapy for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer harboring PIK3CA mutations. By uniquely combining the inhibition of PI3Kα kinase activity with the specific degradation of the mutant p110α protein, inavolisib overcomes the compensatory feedback mechanisms and toxicities that have historically limited pan-PI3K and first-generation inhibitors. Clinical data, most notably from the pivotal Phase III INAVO120 trial, demonstrate that the addition of inavolisib to palbociclib and fulvestrant significantly improves progression-free survival, overall survival, and objective response rates in patients with endocrine-resistant breast cancer. Furthermore, inavolisib exhibits a favorable metabolic safety profile, with markedly lower rates of severe hyperglycemia compared to earlier agents. This review synthesizes the pharmacological activity, molecular mechanisms, structure-activity relationships, current clinical limitations, and future perspectives of inavolisib in the management of PIK3CA-mutated breast cancer.
1. Introduction
Breast cancer is the most common malignant tumor in women globally, with the hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) subtype accounting for approximately 70% of all cases [1]. While the advent of endocrine therapy combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has significantly improved progression-free survival (PFS) in this population, acquired resistance remains a major clinical challenge [1][3]. A primary driver of this resistance is the abnormal activation of the PI3K/AKT/mTOR signaling pathway, predominantly caused by activating mutations in the PIK3CA gene, which occur in 30% to 40% of HR+/HER2- breast cancer cases [1][2][4].
Historically, targeting the PI3K pathway has been hindered by the narrow therapeutic window and severe toxicities (such as hyperglycemia and diarrhea) associated with pan-PI3K inhibitors and first-generation α-specific inhibitors like alpelisib [2][4]. Inavolisib (GDC-0077) is a novel, third-generation, highly selective PI3Kα inhibitor designed to address these limitations. Based on compelling efficacy and safety data from the Phase III INAVO120 trial, inavolisib, in combination with palbociclib and fulvestrant, received approval from the U.S. Food and Drug Administration (FDA) in October 2024 for the treatment of adults with endocrine-resistant, PIK3CA-mutated, HR+/HER2- advanced or metastatic breast cancer [2][3][6].
2. Pharmacological Activity
The pharmacological efficacy of inavolisib has been robustly validated in clinical settings, most notably in the registrational Phase III INAVO120 trial (NCT04191499). This double-blind, placebo-controlled study evaluated the triplet regimen of inavolisib (9 mg orally once daily) plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer who progressed during or within 12 months of adjuvant endocrine therapy [2][3][6].
The addition of inavolisib demonstrated a statistically significant and clinically meaningful improvement in survival metrics. The median PFS was extended to 15.0–17.2 months in the inavolisib arm compared to 7.3 months in the control arm (Hazard Ratio [HR] = 0.42–0.43, p < 0.001) [1][4][5]. The objective response rate (ORR) also saw a substantial increase, reaching 58.4% to 62.7% in the inavolisib group versus 25% to 28.0% in the placebo group [1][4]. Furthermore, the trial reported a significant overall survival (OS) benefit, with a median OS of 34.0 months for the inavolisib triplet compared to 27.0 months for the control group (HR = 0.67) [4][5][6].
3. Molecular Mechanism of Action
Inavolisib exerts its potent antitumor effects through a unique dual-action mechanism that distinguishes it from earlier PI3K inhibitors. First, it acts as an ATP-competitive inhibitor that selectively blocks PI3Kα kinase activity, thereby preventing the conversion of PIP2 to PIP3 and halting the downstream activation of the AKT/mTOR signaling cascade [1][3]. Second, and most uniquely, inavolisib induces the specific degradation of the mutant p110α catalytic subunit protein [1][2]. This targeted degradation fundamentally reduces the reactivation of the PI3K pathway and overcomes the negative feedback loops (such as insulin feedback) that typically lead to hyperglycemia and drug resistance with non-selective inhibitors [1].
When combined with CDK4/6 inhibitors like palbociclib, inavolisib demonstrates profound synergistic effects. PIK3CA mutations often drive resistance to CDK4/6 inhibitors by upregulating Cyclin D1 and activating bypass mitogenic pathways. Inavolisib suppresses PI3K/AKT/mTOR signaling, which downregulates Cyclin D1 expression. Concurrently, the CDK4/6 inhibitor prevents residual CDK activity from phosphorylating the Retinoblastoma (Rb) protein. This complementary blockade produces a deeper and more durable G1-to-S phase cell-cycle arrest and significantly increases apoptosis in tumor cells [1].
4. Structure-Activity Relationship (SAR)
The exceptional selectivity and potency of inavolisib are rooted in its distinct structural characteristics. Inavolisib exhibits greater than 300-fold in vitro selectivity for PI3Kα over other class I PI3K isoforms (PI3Kβ, PI3Kδ, and PI3Kγ) and demonstrates a preferential binding affinity for common oncogenic p110α mutants (such as H1047R) over the wild-type protein [1][3].
Structural biology studies reveal that the compound's pyridine-pyrimidine backbone embeds deeply into the ATP-binding pocket of PI3Kα, effectively blocking the binding of the substrate PIP2. A difluoromethyl oxazoline group forms critical hydrogen bond interactions with the Val828 residue in the hinge region, which significantly enhances binding stability. Furthermore, the amide side chain of inavolisib interacts with the E545 mutation site in the helix domain in a conformation-specific manner. This allows the drug to preferentially recognize and bind to the mutant active state of the kinase, driving its mutant-selective inhibition and subsequent protein degradation [1].
5. Current Limitations
Despite its clinical success, the use of inavolisib is accompanied by several limitations, primarily concerning toxicity management, resistance, and strict patient selection criteria. While inavolisib has a more favorable metabolic safety profile than alpelisib, adverse events still occur. In the INAVO120 trial, common all-grade toxicities included hyperglycemia (59%-63.4%), stomatitis or mucosal inflammation (51%-55.3%), diarrhea (48%-52.2%), and rash (25%-26.7%) [3][4]. Grade 3/4 hyperglycemia was reported in approximately 5.6% to 6.8% of patients, which, while significantly lower than the 37% seen with alpelisib, still requires monitoring [3][4][5]. The combination with palbociclib also results in high rates of grade 3/4 neutropenia (80.2%-82.6%) [4][5]. Prophylactic measures, such as dexamethasone mouthwash for stomatitis, are recommended [2].
Patient selection is highly restrictive; the approved first-line triplet therapy is currently limited to patients with confirmed PIK3CA mutations, first-line endocrine-resistant disease, no prior CDK4/6 inhibitor exposure, and a baseline HbA1c of < 6.0% and fasting blood glucose < 126 mg/dL [2][3]. Additionally, acquired resistance remains inevitable for many patients. Tumor subclones may develop resistance through p21-mediated DNA damage repair, activation of the PDK1 signaling bypass, loss of PTEN, or the acquisition of ESR1 co-mutations [1].
6. Future Perspectives
The future clinical development of inavolisib will likely focus on overcoming resistance and expanding its utility through novel combinations and precision biomarker tracking. Dynamic monitoring of circulating tumor DNA (ctDNA) is emerging as a critical tool to track the longitudinal evolution of PIK3CA mutations, detect the emergence of bypass alterations (e.g., PTEN loss or ESR1 mutations), and guide timely therapeutic modifications before radiographic progression occurs [1][5].
Furthermore, preclinical evidence suggests that PI3K inhibition can remodel the tumor microenvironment by reducing immunosuppressive cell populations and augmenting T-cell effector functions. This provides a strong rationale for exploring triplet or quadruplet combinations involving inavolisib, CDK4/6 inhibitors, and immune checkpoint inhibitors (e.g., PD-1/PD-L1 blockade) [1]. Ongoing translational research utilizing CRISPR screens and phosphoproteomics will be vital to delineate resistance trajectories and identify co-targets, such as mTORC2 or CDK2/Cyclin E, to further optimize inavolisib-based treatment paradigms [1].
